Antivirotika HCV – Glecaprevir - Pibrentasvir V.
Opportunity Score
Why this score?
Opportunity
60 / 100
Complexity
20 / 100
Risk factors
Eligibility criteria not disclosed in notice; bidders may discover disqualifying requirements only after accessing proc...
No required documents list provided; bidders might miss submitting mandatory certifications or references.
Submission deadline in 8 days
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Overview
Moderate opportunityKey Facts
- CZK 237.4M estimated value
- Supplies contract
- 1 lot
- Duration until Sep 2030
- Regular supply of antiviral medicinal products for oral administration containing glecaprevir and pibrentasvir (ATC group J05AP57).
- Treatment of patients in approved indications according to valid Summary of Product Characteristics (SPC) as of bid submission date.
Show full summary
Czech public tender (open procedure) by Institut klinické a experimentální medicíny (IKEM) for the supply of antiviral drugs (glecaprevir/pibrentasvir) for oral administration. Single lot, 48-month contract, estimated value 237,380,000 CZK. Award based solely on lowest price. Submission deadline 2 July 2026. Procurement documents available at https://nen.nipez.cz/profil/ikem but were not analyzed.
Risks
Eligibility criteria not disclosed in notice; bidders may discover disqualifying requirements only after accessing proc...
No required documents list provided; bidders might miss submitting mandatory certifications or references.
Submission deadline in 8 days
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Variants not allowed.
Administrative
- Submission in Czech language only.
- Electronic submission required via Open portal
Requirements may be incomplete.
Award Criteria
Lot 1
Buyer
Name
Institut klinické a experimentální medicíny
Location
Praha, CZE
Website
Buyer profile
Identifier
00023001
Lots (1)
LOT-0001
Antivirotika HCV – Glecaprevir - Pibrentasvir V.
Regular supply of glecaprevir/pibrentasvir tablets for treatment of HCV patients per SPC. Place of performance Prague, Czech Republic. Duration 48 months from October 2026.
CZK 237.4M
Estimated value
Location
Duration
Category
Selection criteria
Deadline
Award details
Value note
Show original TED data
Original TED description
Předmětem veřejné zakázky jsou pravidelné dodávky léčivých přípravků pro perorální podání (tbl flm) s obsahem účinných látek glecaprevir a pibrentasvir (ATC skupina J05AP57) pro léčbu pacientů ve schválených indikacích dle SPC platného ke dni podání nabídky.
Procurement Details
- Publication date
- 02 Jun 2026
- Notice type
- Contract notice — standard
- Languages
- Czech
Reference metadata
- Notice subtype
- 16
- Notice version
- 1
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 381570-2026
- Source notice ID
- 40621d77-450e-452e-a86c-eba7b70273e4
Documents (1)
Similar tenders
Poland – Antineoplastic agents – Dostawa produktów leczniczych i wyrobów medycznych do Wojskowego Instytutu Medycznego – PIB
Romania – General anti-infectives for systemic use and vaccines – Achizitie Medicamente 1 - 2026
Poland – Heparin – Dostawa heparyny, środków przeciwkrwotocznych, produktów leczniczych dla układu sercowo - naczyniowego, środków przeciw nadciśnieniu, środków przeciwbólowych, środków znieczulających, środków antybakteryjnych do użytku ogólnoustrojowego oraz środków antywirusowych do użytku ogólnoustrojowego dla SPWSZ w Szczecinie
Poland – Medicinal products for the blood, blood-forming organs and the cardiovascular system – Dostawa produktów leczniczych dla krwi, organów krwiotwórczych oraz układu krążenia, toksyn, środków leczniczych dla układu oddechowego, środków przeciwnowotworowych i immunomodulacyjnych stosowanych w ramach programów lekowych i chemioterapii, immunoglobulin oraz środków antywirusowych do użytku ogólnoustrojowego dla SPWSZ w Szczecinie
Romania – Various medicinal products – Acord cadru furnizare medicamente PN 11
Belgium – Antibacterials for systemic use – ANTI-INFECTIEUX 2026-2030
Opportunity Score
Why this score?
Opportunity
60 / 100
Complexity
20 / 100
Risk factors
Eligibility criteria not disclosed in notice; bidders may discover disqualifying requirements only after accessing proc...
No required documents list provided; bidders might miss submitting mandatory certifications or references.
Submission deadline in 8 days
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications